Literature DB >> 22879004

Elevated cerebrospinal fluid tau in Wernicke encephalopathy.

Daphne W Frijlink1, Joachim J Tilanus, Gerwin Roks.   

Abstract

Wernicke encephalopathy (WE) commonly presents with oculomotor abnormalities, gait ataxia and confusion. WE can mimic rapidly progressive dementia syndromes, such as Creutzfeldt-Jakob disease (CJD). Cerebrospinal fluid (CSF) tau is frequently used for diagnosis of several dementia subtypes, predominantly CJD and Alzheimer's disease. The combination of very high CSF tau (tau) and normal phosphorylated tau (p-tau) levels is almost exclusively seen in aggressive diseases, such as CJD. The authors present a case of a woman with WE, caused by chronic insufficient dietary intake, with highly elevated CSF tau and normal p-tau. The clinical symptoms and CSF findings raised the suspicion of CJD. However, shortly after immediate treatment with thiamine the patient clinically improved. At follow-up, 2.5 months later, she had made a good recovery. This case of rapidly progressive dementia illustrates that, even in the case of a highly elevated CSF tau, clinicians should be alert for treatable causes such as WE.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22879004      PMCID: PMC4543963          DOI: 10.1136/bcr-2012-006661

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  10 in total

1.  Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke.

Authors:  C Hesse; L Rosengren; N Andreasen; P Davidsson; H Vanderstichele; E Vanmechelen; K Blennow
Journal:  Neurosci Lett       Date:  2001-01-19       Impact factor: 3.046

2.  Wernicke encephalopathy and Creutzfeldt-Jakob disease.

Authors:  A Bertrand; J P Brandel; Y Grignon; V Sazdovitch; D Seilhean; B Faucheux; N Privat; J L Brault; A Vital; E Uro-Coste; M Pluot; F Chapon; C A Maurage; F Letournel; H Vespignani; G Place; C F Degos; K Peoc'h; S Haïk; J J Hauw
Journal:  J Neurol       Date:  2009-03-01       Impact factor: 4.849

3.  Wernicke's encephalopathy mimicking variant Creutzfeldt-Jakob disease.

Authors:  Richard Stone; John S Archer; Matthew Kiernan
Journal:  J Clin Neurosci       Date:  2008-10-01       Impact factor: 1.961

4.  Elevated cerebrospinal fluid tau protein levels in Wernicke's encephalopathy.

Authors:  Sachio Matsushita; Tomohiro Miyakawa; Hitoshi Maesato; Toshifumi Matsui; Akira Yokoyama; Hiroyuki Arai; Susumu Higuchi; Haruo Kashima
Journal:  Alcohol Clin Exp Res       Date:  2008-04-26       Impact factor: 3.455

5.  Elevated levels of tau-protein in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease.

Authors:  M Otto; J Wiltfang; H Tumani; I Zerr; M Lantsch; J Kornhuber; T Weber; H A Kretzschmar; S Poser
Journal:  Neurosci Lett       Date:  1997-04-11       Impact factor: 3.046

Review 6.  Tau and p-tau as CSF biomarkers in dementia: a meta-analysis.

Authors:  Argonde C van Harten; Maartje I Kester; Pieter-Jelle Visser; Marinus A Blankenstein; Yolande A L Pijnenburg; Wiesje M van der Flier; Philip Scheltens
Journal:  Clin Chem Lab Med       Date:  2011-02-23       Impact factor: 3.694

7.  Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease?

Authors:  K Blennow; A Wallin; H Agren; C Spenger; J Siegfried; E Vanmechelen
Journal:  Mol Chem Neuropathol       Date:  1995-12

8.  Phospho-tau/total tau ratio in cerebrospinal fluid discriminates Creutzfeldt-Jakob disease from other dementias.

Authors:  M Riemenschneider; S Wagenpfeil; H Vanderstichele; M Otto; J Wiltfang; H Kretzschmar; E Vanmechelen; H Förstl; A Kurz
Journal:  Mol Psychiatry       Date:  2003-03       Impact factor: 15.992

9.  The role of cerebrospinal fluid 14-3-3 and other proteins in the diagnosis of sporadic Creutzfeldt-Jakob disease in the UK: a 10-year review.

Authors:  G Chohan; C Pennington; J M Mackenzie; M Andrews; D Everington; R G Will; R S G Knight; A J E Green
Journal:  J Neurol Neurosurg Psychiatry       Date:  2010-09-20       Impact factor: 10.154

10.  CSF biomarkers predict rate of cognitive decline in Alzheimer disease.

Authors:  M I Kester; A E van der Vlies; M A Blankenstein; Y A L Pijnenburg; E J van Elk; P Scheltens; W M van der Flier
Journal:  Neurology       Date:  2009-10-27       Impact factor: 9.910

  10 in total
  1 in total

1.  A patient with Korsakoff syndrome of psychiatric and alcoholic etiology presenting as DSM-5 mild neurocognitive disorder.

Authors:  Georgios Nikolakaros; Timo Kurki; Arttu Myllymäki; Tuula Ilonen
Journal:  Neuropsychiatr Dis Treat       Date:  2019-05-22       Impact factor: 2.570

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.